EIKN Eikon Therapeutics, Inc. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$10.79

Period return

-4.21 (-28.07%)

Volume

212.5K

2026-06-01O $10.84 H $11.37 L $10.54 C $10.79MA5 $10.44MA20 $10.86MA60 $10.86

6M · 80 barsYahoo Finance · USD2026-02-05 → 2026-06-01

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 05. 12.LowSELL21 days ago
Wedbush: Underperform
US analyst rating / recommendation change.
2026. 03. 31.LowSELL2 months ago
Wedbush: Underperform
US analyst rating / recommendation change.
2026. 03. 03.MediumBUY3 months ago
Cantor Fitzgerald: Overweight
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $25.2 · 5 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.

Sector: Healthcare
Industry: Biotechnology
HQ: Millbrae, CA, United States
Fiscal year end: —
Employees: 384
IPO date: —

View details →

2026. 03. 02.MediumBUY3 months ago

JP Morgan: Overweight